Autophagy Neurotherapeutics, Inc.
11350 SW Village Parkway
Port St. Lucie, FL 34987
Port St. Lucie, Florida, U.S., October 31, 2017 - Autophagy Neurotherapeutics (ANT) and the Torrey Pines Institute for Molecular Studies (TPIMS) announced today that they have entered into a licensing agreement to commercialize ANT’s novel small molecule drugs developed at TPIMS for treating Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease (AD).
Over the past three years, ANT has utilized the concepts developed by Nobel Prize winner Dr. Yoshinori Ohsumi for his discovery of the mechanisms that control autophagy. Autophagy is a process by which the cells degrade used proteins and other cellular waste material thereby maintaining balance in the cell. ANT is focused on two very promising lead compounds currently in development. One of these lead compounds uses the technological approach of modulating autophagy through the autophagy-lysosome pathway (ALP). Modulation of the ALP is achieved by both genetic manipulations and a small molecule compound, which robustly enhances autophagy and clears toxic protein aggregates in cellular models of AD. Dr. Lakshmana, an Associate Member at TPIMS and ANT's Chief Scientific Officer, believes that these compounds may be useful in AD as well as other neurological disorders, including ALS and Parkinson's disease (PD).
ANT will use this technology to develop additional compounds active against neurodegenerative diseases. TPIMS's technologies enable the screening of tens of millions of compounds while requiring the testing of only hundreds of samples to identify hits. This greatly reduces the time and expense involved in initiating research programs with the aim of developing new treatment options for patients.
Donald Hudson, Chairman & CEO of Autophagy Neurotherapeutics, comments: "We are delighted to be working with the TPIMS team in incubator space at TPIMS, which has a great history of innovation in developing huge small molecule and peptide libraries that can be screened in a quick and efficient format."
Dr Richard Houghten, Founder and CEO of TPIMS, states: "It is exciting to partner with Autophagy Neurotherapeutics, a company with a record of developing novel small molecule product candidates. TPIMS possesses trillions of peptides and millions of small molecules systematically arranged for high-throughput screening in a variety of biological assay formats, including phenotypic assays. Additionally, the TPIMS collections of classic small molecules approximately 10 million classic small molecules and literally billions readily are readily available for testing."
About Autophagy Neurotherapeutics, Inc.
Autophagy Neurotherapeutics, Inc. (Autophagy) is an early‐stage biotechnology company, located in incubator labs at Torrey Pines Institute for Molecular Studies (TPIMS) in Port St. Lucie, FL, and is focused on lead optimization and pre‐clinical development of small molecule drugs for treating ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease (AD) and other neurodegenerative diseases. The technological approach is to modulate autophagy, which is the brain’s system for eliminating toxic proteins. It is emerging as one of the best ways to develop therapeutics for most neurodegenerative diseases. ALS is the company’s first focus because the disease is clearly replicated in mouse models, as it only affects motor neurons and a smaller number of toxic proteins that cause the disease.
About Torrey Pines Institute for Molecular Studies, Inc.
Torrey Pines Institute for Molecular Studies (TPIMS) is a non-profit institute dedicated to conducting basic research to advance the understanding of human disease and the improvement of human health. TPIMS’ scientists conduct research in fields associated with a wide variety of major medical conditions, including addiction, Alzheimer’s, arthritis, cancer, diabetes, heart disease, infectious disease, inflammatory disorders, multiple sclerosis, obesity, pain management, regenerative medicine and new methods for drug discovery.
For further information, please contact:
Donald Hudson, Chairman and CEO
8814 S. Sea Oaks Way #306, Vero Beach, FL 32963
Communications Department, Torrey Pines Institute for Molecular Studies
11350 SW Village Pkwy, Port St. Lucie, FL 34987